Compare · BDX vs SI
BDX vs SI
Side-by-side comparison of Becton Dickinson and Company (BDX) and Shoulder Innovations Inc. (SI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 140.6x SI ($296.1M).
- Over the past year, BDX is down 12.3% and SI is down 5.9% - SI leads by 6.4 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 1 for SI).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Shoulder Innovations Inc.
- Price
- $151.22+1.14%
- $14.20-1.53%
- Market cap
- $41.65B
- $296.1M
- 1M return
- +4.55%
- +10.16%
- 1Y return
- -12.33%
- -5.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 10
- 1
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Shoulder Innovations Inc.
Silvergate Capital Corporation operates as a bank holding company for Silvergate Bank that provides banking products and services to business and individual clients in the United States and internationally. The company accepts deposit products, including interest and noninterest bearing demand accounts, money market and savings accounts, and certificates of deposit accounts. Its loan products comprise one-to-four family real estate loans, multi-family real estate loans, commercial real estate loans, construction loans, commercial and industrial loans, mortgage warehouse loans, and reverse mortgage loans, as well as consumer loans and other loans secured by personal property. The company also provides cash management services for digital currency-related businesses. The company was founded in 1988 and is headquartered in La Jolla, California.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest SI
- Shoulder Innovations to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form 10-Q filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
- CEO & Executive Chairman Ball Robert Joseph exercised 10,000 shares at a strike of $2.48, increasing direct ownership by 3% to 300,018 units (SEC Form 4)
- SEC Form DEF 14A filed by Shoulder Innovations Inc.
- SEC Form DEFA14A filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Shoulder Innovations Initiates Full Commercial Launch of the InSet™ I-135RFX Humeral Stem
- Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026